Skip to content
Review

Antithrombotic therapy to minimize total events after ACS or PCI in atrial fibrillation: insights from AUGUSTUS.

Aug 2026 · Current Opinion in Cardiology · Vol 41, pp. 593-599 · 0 citations · 22 references
Medicine

TL;DR

For patients with AF after ACS or PCI, DOAC-based dual antithrombotic therapy provides the most favorable cumulative safety-efficacy balance, and future research should focus on the timing of aspirin discontinuation and validate recurrent-event endpoints.

Abstract

Purpose

OF REVIEW Antithrombotic therapy for patients with atrial fibrillation (AF) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) requires balancing prevention of stroke and coronary events against bleeding. Recent recurrent-event and patient-centered analyses of AUGUSTUS make this review timely by reframing treatment benefit beyond first events. RECENT

Findings

Four dedicated trials support dual antithrombotic therapy with direct oral anticoagulants (DOAC) plus P2Y12 inhibitor and early aspirin withdrawal to reduce bleeding without significant increase in ischemic events. However, aspirin-free strategies differ by anticoagulation indication: in patients without anticoagulation, very early aspirin withdrawal after ACS or PCI may increase the risk of coronary events, whereas in patients with AF receiving anticoagulation, oral anticoagulation may assume the early antithrombotic role of aspirin. AUGUSTUS showed that apixaban and placebo each reduced bleeding compared with vitamin K antagonist and aspirin. The recent total-event analyses further showed lower cumulative bleeding with apixaban than with vitamin K antagonist, and substantially greater cumulative bleeding with randomized aspirin than with placebo, along with similar total ischemic events and hospitalizations. SUMMARY For patients with AF after ACS or PCI, DOAC-based dual antithrombotic therapy provides the most favorable cumulative safety-efficacy balance. Future research should focus on the timing of aspirin discontinuation and validate recurrent-event endpoints.

View source

Similar papers

Review Open access Sep 2026

Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Antithrombotic therapy management in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains challenging as it requires simultaneous protection from cardioembolism and coronary ischemic events while minimizing bleeding. The coexistence of these competing risks, along with thei...

Carmelo Raffo, D. Giacoppo, D. Capodanno et al. · 0 citations
Open access Feb 2026

Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial

ADONIS-PCI is among the first randomized evaluations of a reduced-dose long-term ticagrelor strategy combined with dabigatran in patients with AF and ACS undergoing PCI, addressing an important evidence gap in the selection and dosing of P2Y12 inhibition when aspirin is discontinued early in this high-risk population.

M. Jaguszewski, Aleksandra Gąsecka-van der Pol, N. Gilis-Malinowska et al. · 0 citations
Open access Aug 2026

Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis.

A patient-level meta-analysis of randomized trials evaluating antithrombotic strategies in patients with AF undergoing PCI found the risk of cardiovascular death, myocardial infarction, or stroke did not significantly differ according to whether patients received a DOAC or VKA, whereas a modest increase in risk with si...

M. Chiarito, R. Mehran, Michael C. Gibson et al. · 0 citations
Open access Aug 2026

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.

Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications, and these findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population.

Konstantinos D. Rizas, K. Mourouzis, D. Rath et al. · 3 citations
Sep 2026

Antithrombotic Therapy in Patients with Chronic Coronary Disease on Anticoagulation: Evidence from Contemporary Trials.

INTRODUCTION Chronic coronary disease (CCD) commonly coexists with long-term oral anticoagulation (OAC), particularly for atrial fibrillation (AF). Combination antiplatelet therapy increases bleeding, whereas ischemic protection with OAC alone remains a concern. We critically appraised contemporary evidence and guideli...

Sukhila Reddy, Lakshmi Kattamuri, Muhammad Asif et al. · 0 citations
Oct 2026

Individualized Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndrome: Current SAPT Strategies and the Potential Role of Indobufen.

Current evidence suggests that indobufen-based DAPT may provide comparable ischemic protection with fewer bleeding or gastrointestinal adverse events in selected PCI patients, particularly those with aspirin intolerance, gastrointestinal vulnerability, or high bleeding risk.

Jia-Hui Chai, Xue-Bo Li, Qian Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.